Filing Flows › Comparisons › DFNS vs PBSV
T3 Defense vs Pharma-Bio Serv: DFNS and PBSV compared
T3 Defense is the larger company: $4.0M of revenue in its latest quarter (Q2 2026) against $2.3M for Pharma-Bio Serv (Q3 FY26). Pharma-Bio Serv is more profitable, with an operating margin of -3.1% against -84.5%.
Where the money goes: DFNS and PBSV
T3 Defense (DFNS) · Q2 2026
T3 Defense, Q2 2026: revenue $4.0M, operating margin -84.5%, net loss $81.4M, operating cash flow −$4.9M. The chart follows the revenue to costs, profit and cash.
Pharma-Bio Serv (PBSV) · Q3 FY26
Pharma-Bio Serv, Q3 FY26: revenue $2.3M (+19% year over year), operating margin -3.1%, net loss $14K, operating cash flow $61K. The chart follows the revenue to costs, profit and cash.
| T3 Defense (DFNS) | Pharma-Bio Serv (PBSV) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 FY26 |
| Revenue | $4.0M | $2.3M |
| Revenue growth, Y/Y | — | +19% |
| Operating margin | -84.5% | -3.1% |
| Net earnings | −$81.4M | −$14K |
| Net margin | — | -0.6% |
| Operating cash flow | −$4.9M | $61K |
| Free cash flow | — | $60K |
Questions
Which is bigger, T3 Defense or Pharma-Bio Serv?
T3 Defense is the larger company: $4.0M of revenue in its latest quarter (Q2 2026) against $2.3M for Pharma-Bio Serv (Q3 FY26).
Is T3 Defense or Pharma-Bio Serv growing faster?
Pharma-Bio Serv is more profitable, with an operating margin of -3.1% against -84.5%.
More: T3 Defense earnings · how T3 Defense makes money · Pharma-Bio Serv earnings · how Pharma-Bio Serv makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 18, 2026; 10-Q filed Sep 14, 2026). Fiscal quarters can end on different dates. Not investment advice.